Andrew Hill Investment Advisors Inc. Purchases 1,430 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Andrew Hill Investment Advisors Inc. increased its holdings in Vertex Pharmaceuticals by 21.8%, owning 8,003 shares valued at approximately $3.56 million, making it the firm's 17th largest position.
• Multiple hedge funds, including Vanguard Group Inc. and Price T Rowe Associates Inc., also reported increases in their investments in Vertex, with institutional investors now holding 90.96% of the company's stock.
• Vertex Pharmaceuticals recently released earnings, reporting $4.52 EPS and $2.94 billion in revenue for the quarter, surpassing analyst expectations.

Andrew Hill Investment Advisors Inc. increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 21.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,003 shares of the pharmaceutical company's stock after buying an additional 1,430 shares during the period. Vertex Pharmaceuticals comprises approximately 2.9% of Andrew Hill Investment Advisors Inc.'s investment portfolio, making the stock its 17th biggest holding. Andrew Hill Investment Advisors Inc.'s holdings in Vertex Pharmaceuticals were worth $3,563,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Activest Wealth Management purchased a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth about $31,000. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $32,000. Finally, Mpwm Advisory Solutions LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 90.96% of the company's stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs purchased 5,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company's stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on VRTX. Wall Street Zen downgraded Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, August 22nd. HC Wainwright dropped their price target on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research report on Tuesday, August 5th. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 price target for the company in a research report on Wednesday, August 6th. Stifel Nicolaus lowered their price objective on Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating for the company in a research note on Tuesday, August 5th. Finally, JPMorgan Chase & Co. boosted their target price on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $496.05.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX traded down $3.99 during trading hours on Friday, hitting $383.12. The company had a trading volume of 3,393,840 shares, compared to its average volume of 1,391,374. The firm has a fifty day moving average price of $414.44 and a 200-day moving average price of $450.09. The stock has a market capitalization of $98.23 billion, a price-to-earnings ratio of 27.39 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. The business had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business's revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.